...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Message: A simple question....is Saturday make or break?

Yes, of course.

Better data = more derisking

Worse data = more risk

Bad enough data = RVX abandons the CVD indication

Data, data, data

Tick, tock, tick, tock

New Message
Please login to post a reply